Loading stock data…
Ascendis Pharma A/S (ASND)
$253.86+1.20 (+0.47%)
Market ClosedLast close Jul 24
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ascendis Pharma A/S in the Healthcare sector is trading at $253.86 with a market capitalization of $13.8B. Wall Street consensus targets $304.53 (18 analysts), implying a +20.0% move over the next 12 months. The stock is currently 10% below its 52-week high of $282.15, remaining 12.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $246.60M↓ | $247.50M↑ | $213.63M↑ | $158.04M↑ | $100.95M |
| Gross Profit | $229.09M↑ | $223.90M↑ | $191.28M↑ | $126.60M↑ | $83.44M |
| Operating Income | $24.81M↑ | $6.44M↓ | $11.00M↑ | -$52.95M↑ | -$104.21M |
| Net Income | $629.34M↑ | -$33.56M↑ | -$60.99M↓ | -$38.85M↑ | -$94.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.44
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
101.63%
Volume
Today's trading volume
360,735
Recent News
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The fund reported strong absolute returns and modestly outperformed the Russell 2000® Growth Index, which gained 25.7%. Global equities rebounded as resilient US growth, moderating inflation, strong earnings and […]
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia
Ascendis Pharma reported new two-year radiographic outcomes from its pivotal ApproaCH trial of TransCon CNP (YUVIWEL) in children with achondroplasia. The data show continued improvements in lower limb alignment and maintained growth velocity over two years, with treatment generally well tolerated. This update follows recent US approval of TransCon CNP (YUVIWEL) and comes as the therapy remains under regulatory review in Europe. For investors watching Ascendis Pharma (NasdaqGS:ASND), the...
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24%
Ascendis Pharma stock has climbed 24.0% over the past month, yet the current valuation checks and market multiples point to a picture that is not clearly cheap or clearly expensive. The 24.0% gain over the past 30 days suggests investors have recently been willing to pay up for Ascendis Pharma, which raises the bar for what the fundamentals need to deliver next. Expectations around Ascendis Pharma's ability to turn its pipeline into sustained revenue growth can support the current share...
Why Crinetics Stock Soared 99% This Week
Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s $10 Billion All-Cash Bid Fuels the Surge The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 ... Why Crinetics Stock Soared 99% This Week